Last updated on September 2016

Continuation Study of Entinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumors


Brief description of study

The objectives of this study are to explore different dosing levels and schedules of entinostat in combination with pembrolizumab in patients with advanced solid tumors, in terms of safety, tolerability, pharmacokinetics (PK), impact on immune correlatives, and efficacy

Detailed Study Description

This is a Phase 1, open-label, single center, randomized study to assess the safety and tolerability of 3 different dose regimens of entinostat in combination with pembrolizumab in patients with advanced solid tumors who previously completed Study SNDX-275-0140 (NCT02897778). Up to 30 patients will be randomized in a 1:1:1 fashion to one of three arms. In the event that greater than or equal to 2 out of the first 6 patients randomized experience a dose-limiting toxicity, the next patient randomized to that Arm will receive treatment at a reduced starting dose as outlined in the protocol.

Clinical Study Identifier: NCT02909452

.

Contact Investigators or Research Sites near you

Start Over

Please choose location

View all locations

Anthony W Tolcher, MD

The START Center for Cancer Care
San Antonio, TX United States
  Connect »